
CONTENTS

| Chapter No. | Topic No. | Title of Topic | Page No. |
|--------------------------------------|------------------|--|-----------------|
| I | | List of Figures | I |
| II | | List of Tables | IX |
| III | | List of Materials | XVII |
| IV | | List of Instruments/Equipments | XX |
| V | | Abstract | XXII |
| Chapter-1: Introduction | | | |
| 1.0 | 1.1 | Osteoporosis | 1 |
| | 1.1.1 | Introduction | 1 |
| | 1.1.2 | Clinical risk factors for Osteoporosis | 2 |
| | 1.1.3 | Diagnosis of Osteoporosis | 3 |
| | 1.1.4 | Treatment and management of Osteoporosis | 4 |
| | 1.2 | Nanocarriers for drug delivery | 6 |
| | 1.2.1 | Glycerosomes | 7 |
| | 1.2.2 | Polyelectrolyte complex nanoparticles | 7 |
| | 1.3 | Drug candidate selection | 8 |
| | 1.3.1 | Risedronate Sodium (Bisphosphonate) | 8 |
| | 1.3.2 | Atorvastatin (statins) | 8 |
| | 1.4 | Aim and Objectives | 8 |
| | 1.5 | Hypothesis | 9 |
| | 1.6 | Plan of work | 9 |
| | 1.7 | References | 11 |
| Chapter- 2: Literature Review | | | |
| 2.0 | 2.1 | Osteoporosis | 14 |
| | 2.1.1 | Bone organization | 14 |
| | 2.1.2 | Bone matrix | 16 |
| | 2.1.3 | Pathophysiology of Osteoporosis | 18 |

| | | |
|-------|---|----|
| 2.1.4 | Risk factors/Causes of Osteoporosis | 20 |
| 2.1.5 | Types of osteoporosis | 21 |
| 2.1.6 | Bone remodelling Process | 22 |
| 2.1.7 | Treatment of osteoporosis | 24 |
| 2.2 | Risedronate Sodium (RSNa) | 28 |
| 2.2.1 | Risedronate sodium profile | 28 |
| 2.2.2 | Pharmacokinetics | 29 |
| 2.2.3 | Pharmacodynamics | 30 |
| 2.2.4 | Drug Interaction | 30 |
| 2.2.5 | Dose | 30 |
| 2.3 | Atorvastatin calcium (ATO) | 32 |
| 2.3.1 | Atorvastatin profile | 32 |
| 2.3.2 | Pharmacokinetics | 33 |
| 2.3.3 | Food interaction | 34 |
| 2.3.4 | Dose | 34 |
| 2.4 | Transdermal Drug Delivery Systems | 36 |
| 2.4.1 | Drug absorption via the skin | 38 |
| 2.4.2 | Challenges for transdermal drug delivery | 39 |
| 2.4.3 | Techniques for enhancing transdermal delivery | 40 |
| 2.5 | Transdermal drug delivery for treatment of osteoporosis | 42 |
| 2.6 | Nanocarriers | 44 |
| 2.7 | References | 51 |

Chapter- 3: Analytical Techniques

| | | |
|-------|---|----|
| 3.1 | Equipments | 68 |
| 3.2 | Analytical techniques | 68 |
| 3.3 | General methods for validation of analytical methods | 68 |
| 3.4 | Analytical technique for Atorvastatin (ATO) | 70 |
| 3.4.1 | Calibration curve of Atorvastatin by UV Visible spectrophotometer | 70 |
| 3.4.2 | Calibration curve in Saline phosphate buffer (pH 7.4) | 71 |
| 3.4.3 | Calibration curve in Phosphate buffer (pH 5.5) | 74 |
| 3.4.4 | Quantification of ATO by RP-HPLC | 76 |
| 3.4.5 | Quantification of ATO in plasma by RP-HPLC | 79 |
| 3.5 | Analytical technique for Risedronate sodium | 84 |
| 3.5.1 | Calibration curve of Risedronate sodium in distilled water | 84 |
| 3.5.2 | Quantification of RSNa by RP-HPLC | 85 |

| | | | |
|--|---------|--|-----|
| | 3.5.3 | Quantification of RSNa in plasma by RP-HPLC | 88 |
| | 3.6 | References | 93 |
| Chapter-4: Preformulation Study | | | |
| | 4.1 | Preformulation study | 94 |
| | 4.1.1 | Authentication of drugs | 94 |
| | 4.1.1.1 | Organoleptic properties of drugs | 94 |
| | 4.1.1.2 | Melting point determination | 94 |
| | 4.1.1.3 | Differential Scanning Calorimeter (DSC) analysis | 94 |
| | 4.1.1.4 | Fourier transform infrared (FTIR) analysis | 94 |
| | 4.1.1.5 | Determination of λ_{\max} by UV-Vis Spectrophotometer | 95 |
| 4.0 | 4.2 | Drug-excipients compatibility study | 95 |
| | 4.3 | Results and discussion: | 96 |
| | 4.3.1 | Organoleptic characteristics | 96 |
| | 4.3.2 | Melting point determination | 96 |
| | 4.3.3 | FTIR analysis | 96 |
| | 4.3.4 | DSC analysis | 98 |
| | 4.3.5 | Determination of λ_{\max} by UV-Vis Spectrophotometer | 99 |
| | 4.4 | Drug-excipients compatibility study | 99 |
| | 4.5 | References | 103 |
| Chapter-5: Formulation development of ATO Loaded Glycerosomes | | | |
| | 5.1 | Glycerosomes | 104 |
| | 5.2 | Selection of method for preparation of glycerosomes | 104 |
| | 5.3 | Selection of lipids | 105 |
| | 5.4 | Drug-Excipients interaction studies by FTIR | 106 |
| | 5.5 | Identification of independent variables and qualitative risk assessment using Ishikawa diagram | 106 |
| | 5.6 | Optimization | 106 |
| | 5.6.1 | Optimization of variables | 106 |
| 5.0 | 5.6.2 | Optimization of ATO loaded glycerosomes by Definitive Screening Design | 107 |
| | 5.6.3 | Validation of Check Point Batch | 108 |
| | 5.7 | Characterization of glycerosomes | 108 |
| | 5.8 | Optimization and impact of glycerol concentration on ATO loaded glycerosomes | 110 |
| | 5.8.1 | Deformability Index | 110 |
| | 5.8.2 | Rheological study | 110 |
| | 5.8.3 | In vitro drug release study | 111 |
| | 5.8.4 | Ex vivo skin permeation study | 112 |

| | | |
|--------|--|-----|
| 5.8.5 | In vitro cell line study | 114 |
| 5.9 | Stability study | 116 |
| 5.10 | Results and discussion: | 117 |
| 5.11 | Preliminary screening for ATO loaded glycosomes | 117 |
| 5.11.1 | Risk analysis and mitigation | 117 |
| 5.11.2 | Selection of method of preparation and lipid | 118 |
| 5.11.3 | Screening and optimization of process parameters of lipid film formation | 120 |
| 5.11.4 | Screening and optimization of process parameters for preparation of glycosomes | 122 |
| 5.11.5 | Screening and optimization of formulation parameters for glycosomes preparation | 125 |
| 5.12 | Design of experiment: Definitive screening design for optimization of glycosomes | 128 |
| 5.12.1 | Design matrix | 128 |
| 5.13 | Effect of independent variables on vesicle size | 130 |
| 5.14 | Effect of independent variables on % EE | 137 |
| 5.15 | Desirability plot and overlay plot for optimization | 143 |
| 5.16 | Graphical optimization to generate control space | 146 |
| 5.17 | Analysis of design space | 146 |
| 5.18 | Point prediction and confirmation | 147 |
| 5.19 | Physicochemical characterization of optimized batch | 148 |
| 5.19.1 | Vesicle size, PDI and zeta potential determination | 148 |
| 5.19.2 | Entrapment efficiency and % DLC | 149 |
| 5.19.3 | Surface morphological study | 150 |
| 5.19.4 | FTIR Study | 150 |
| 5.19.5 | Residual solvent study | 151 |
| 5.20 | Optimization and impact of glycerol concentration on physicochemical characterization of ATO loaded glycosomes | 151 |
| 5.21 | Rheological studies | 153 |
| 5.22 | In vitro drug release study | 154 |
| 5.23 | Ex vivo skin permeation study | 158 |
| 5.24 | Optimization of glycerol concentration in ATO loaded glycosomes | 161 |
| 5.25 | In vitro cell viability study | 161 |
| 5.26 | In vitro cell permeability study | 162 |
| 5.27 | Stability study | 164 |
| 5.28 | References | 167 |

Chapter-6: Formulation development of RSNa Loaded Glycosomes

| | | | |
|--------|--|--|-----|
| 6.0 | 6.1 | Selection of method for preparation of glycosomes | 173 |
| | 6.2 | Selection of lipids | 174 |
| | 6.3 | Drug-Excipients interaction studies by FTIR | 174 |
| | 6.4 | Identification of independent variables and qualitative risk assessment using Ishikawa diagram | 174 |
| | 6.5 | Optimization | 174 |
| | 6.6 | Screening and optimization of process variables | 175 |
| | 6.7 | Screening and optimization of formulation variables | 175 |
| | 6.8 | Optimization of RSNa loaded glycosomes by Definitive Screening Design (DSD) | 175 |
| | 6.9 | Characterization of RSNa loaded glycosomes | 176 |
| | 6.10 | Effect of glycerol concentration on RSNa loaded glycosomes | 177 |
| | 6.11 | In vitro drug release study | 178 |
| | 6.12 | Ex vivo skin permeation study | 178 |
| | 6.13 | In vitro cell line study: | 179 |
| | 6.14 | Stability study | 180 |
| | 6.15 | Results and discussion: | 181 |
| | 6.16 | Preliminary screening for RSNa loaded glycosomes | 181 |
| | 6.16.1 | Risk analysis and mitigation | 181 |
| | 6.16.2 | Selection of method of preparation and lipid | 182 |
| | 6.16.3 | Screening and optimization of process parameters of lipid film formation | 184 |
| | 6.16.4 | Screening and optimization of process parameter for preparation of glycosomes | 184 |
| | 6.16.5 | Screening and optimization of formulation parameters on glycosomes preparation | 188 |
| | 6.17 | Definitive screening design for optimization of glycosomes | 190 |
| | 6.18 | Design Matrix | 190 |
| | 6.18.1 | Effect of independent variables on vesicle size | 192 |
| | 6.18.2 | Effect of independent variables on % EE | 198 |
| | 6.19 | Desirability plot and overlay plot for optimization | 204 |
| | 6.20 | Graphical optimization to generate control space | 207 |
| | 6.21 | Analysis of design space | 208 |
| | 6.22 | Point prediction and confirmation | 209 |
| | 6.23 | Physicochemical characterization of optimized batch | 209 |
| 6.23.1 | Vesicle size, PDI and zeta potential determination | 209 | |
| 6.23.2 | Entrapment efficiency and % DLC | 210 | |

| | | |
|--------|---|-----|
| 6.23.3 | Morphological investigation | 211 |
| 6.23.4 | FTIR Study | 211 |
| 6.23.5 | Residual solvent study | 212 |
| 6.24 | Optimization and impact of glycerol concentration on physicochemical characterization of RSNa loaded glycosomes | 212 |
| 6.25 | Rheological studies | 213 |
| 6.26 | In vitro drug release study | 215 |
| 6.27 | Ex vivo skin permeation study | 218 |
| 6.28 | Optimization of glycerol concentration in RSNa loaded glycosomes | 221 |
| 6.29 | In vitro cell viability study | 221 |
| 6.30 | In vitro cell permeability study | 223 |
| 6.31 | Stability study | 224 |
| 6.32 | References | 227 |

Chapter-7: Formulation development of ATO Loaded PECN

| | | |
|--------|---|-----|
| 7.1 | Introduction | 231 |
| 7.2 | Preparation of ATO loaded PECN | 231 |
| 7.3 | Selection of polyelectrolytes | 231 |
| 7.4 | Optimization | 231 |
| 7.5 | Screening and optimization of process and formulation parameters | 232 |
| 7.6 | Experimental design | 232 |
| 7.7 | Physicochemical characterization of ATO loaded PECN | 233 |
| 7.8 | In vitro drug release study | 235 |
| 7.9 | Ex vivo skin permeation study | 235 |
| 7.10 | In vitro cell line study | 236 |
| 7.11 | Stability study | 237 |
| 7.12 | Results and discussion | 238 |
| 7.13 | Preliminary screening for ATO loaded PECN | 238 |
| 7.13.1 | Selection of polyelectrolytes | 238 |
| 7.13.2 | Risk analysis and mitigation | 239 |
| 7.13.3 | Screening and optimization of process parameters for preparation of PECN | 241 |
| 7.13.4 | Screening and optimization of formulation parameters for PECN preparation | 242 |
| 7.14 | Experimental design and analysis of results | 246 |
| 7.14.1 | Effects of independent variables on particle size | 247 |
| 7.14.2 | Effects of variables on % EE | 254 |

| | | |
|--------|--|-----|
| 7.15 | Desirable plot and overlay plot for optimization | 259 |
| 7.16 | Assessment of the optimized ATO loaded PECN | 261 |
| 7.17 | Graphical optimization to generate control space | 262 |
| 7.18 | Analysis of design space | 263 |
| 7.19 | Point prediction and confirmation | 264 |
| 7.20 | Physicochemical characteristics of ATO loaded PECN | 265 |
| 7.20.1 | Particle size, % EE, % drug loading capacity and surface charge analysis | 265 |
| 7.20.2 | Surface morphological analysis | 266 |
| 7.20.3 | FTIR analysis | 267 |
| 7.20.4 | DSC analysis | 268 |
| 7.20.5 | X-ray diffraction study | 269 |
| 7.21 | In vitro drug release study | 269 |
| 7.22 | Ex vivo skin permeation study | 272 |
| 7.23 | In vitro cell viability study | 274 |
| 7.24 | In vitro cell permeability study | 275 |
| 7.25 | Stability study | 277 |
| 7.26 | References | 279 |

Chapter-8: Formulation development of RSNa Loaded PECN

| | | |
|--------|---|-----|
| 8.1 | Preparation of RSNa loaded PECN | 284 |
| 8.2 | Selection of polyelectrolytes | 284 |
| 8.3 | Optimization | 284 |
| 8.4 | Screening and optimization of process and formulation parameters | 284 |
| 8.5 | Experimental design | 285 |
| 8.6 | Physicochemical characterization of RSNa loaded PECN | 286 |
| 8.7 | In vitro drug release study | 286 |
| 8.8 | Ex vivo skin permeation study | 287 |
| 8.9 | In vitro cell line study | 287 |
| 8.10 | Stability study | 289 |
| 8.11 | Results and discussion | 290 |
| 8.12 | Preliminary screening for RSNa loaded PECN | 290 |
| 8.12.1 | Selection of polyelectrolytes | 290 |
| 8.12.2 | Risk analysis and mitigation | 291 |
| 8.12.3 | Screening and optimization of process parameters for preparation of PECN | 293 |
| 8.12.4 | Screening and optimization of formulation parameters for PECN preparation | 294 |
| 8.13 | Experimental design and analysis of results | 297 |

| | | |
|--------|--|-----|
| 8.13.1 | Effects of independent variables on particle size | 298 |
| 8.13.2 | Effects of variables on % EE | 304 |
| 8.14 | Desirable plot and overlay plot for optimization | 310 |
| 8.15 | Assessment of the optimized RSNa loaded PECN | 312 |
| 8.16 | Graphical optimization to generate control space | 312 |
| 8.17 | Analysis of design space | 313 |
| 8.18 | Point prediction and confirmation | 314 |
| 8.19 | Physicochemical characteristics of RSNa loaded PECN | 314 |
| 8.19.1 | Particle size, % EE, % drug loading capacity and surface charge analysis | 314 |
| 8.19.2 | Surface morphological analysis | 316 |
| 8.19.3 | FTIR analysis | 316 |
| 8.19.4 | DSC analysis | 317 |
| 8.19.5 | X-ray diffraction study | 318 |
| 8.20 | In vitro drug release study | 318 |
| 8.21 | Ex vivo skin permeation study | 321 |
| 8.22 | In vitro cell viability study | 323 |
| 8.23 | In vitro cell permeability study | 324 |
| 8.24 | Stability study | 326 |
| 8.25 | References | 328 |

Chapter-9: Nanocarriers Incorporated Transdermal Patch

| | | |
|---------|---|-----|
| 9.1 | Transdermal Patch | 334 |
| 9.2 | Preparation of transdermal patch | 334 |
| 9.3 | Selection of polymer | 334 |
| 9.4 | Screening and optimization of process and formulation parameters for preparation of transdermal patch | 334 |
| 9.5 | Incorporation of glycosomes into transdermal patch | 335 |
| 9.5.1 | Incorporation of PECN into transdermal patch | 335 |
| 9.5.1.1 | Selection and optimization of penetration enhancer | 335 |
| 9.5.1.2 | Optimization of concentration of permeation enhancer | 336 |
| 9.6 | Physicochemical characteristics of transdermal patch | 336 |
| 9.6.1 | Physical Attributes | 336 |
| 9.6.2 | Percentage moisture uptake and moisture content | 337 |
| 9.6.3 | Tensile strength | 337 |
| 9.6.4 | Drug content | 338 |
| 9.7 | Ex vivo skin permeation and deposition study | 338 |
| 9.8 | Evaluation of skin structure by FTIR study | 339 |

| | | |
|----------|--|-----|
| 9.9 | Ex vivo skin permeation analysis by using fluorescence microscopy | 339 |
| 9.10 | Histopathological studies | 340 |
| 9.11 | Stability study | 340 |
| 9.12 | Results and discussion | 341 |
| 9.13 | Selection of polymers for transdermal patch preparation | 341 |
| 9.14 | Screening and optimization of process and formulation parameters | 343 |
| 9.14.1 | Screening and optimization of process parameters for transdermal patch | 343 |
| 9.14.1.1 | Selection of drying condition | 343 |
| 9.14.1.2 | Selection of drying time | 343 |
| 9.14.2 | Screening and optimization of formulation parameters for transdermal patch | 344 |
| 9.14.2.1 | Screening and optimization of HPMC K4M concentration | 345 |
| 9.14.2.2 | Selection of plasticizer | 345 |
| 9.14.2.3 | PEG-400 concentration | 346 |
| 9.15 | Incorporation of nanocarriers into transdermal patches | 349 |
| 9.15.1 | Glycosomes incorporated transdermal patches | 349 |
| 9.15.1.1 | ATO loaded glycosomal transdermal patch - Formulation development | 349 |
| 9.15.1.2 | RSNa loaded glycosomal transdermal patch - Formulation development | 351 |
| 9.15.2 | PECN incorporated transdermal patches | 353 |
| 9.15.2.1 | Screening and optimization of permeation enhancer | 353 |
| 9.15.2.2 | Screening and optimization of concentration of permeation enhancer | 353 |
| 9.15.2.3 | ATO-PECN transdermal patch - Formulation development | 354 |
| 9.15.2.4 | RSNa-PECN transdermal patch - Formulation development | 355 |
| 9.16 | Ex-vivo skin permeation study | 358 |
| 9.16.1 | For ATO loaded glycosomal transdermal patch | 358 |
| 9.16.2 | For RSNa loaded glycosomal transdermal patch | 360 |
| 9.16.3 | ATO-PECN transdermal patch | 362 |
| 9.16.4 | RSNa-PECN incorporated transdermal patch | 365 |
| 9.17 | Evaluation of skin structure integrity by FTIR-ATR study | 367 |
| 9.18 | Ex vivo analysis of drug permeation through skin using fluorescence microscopy | 369 |

| | | | |
|--|----------|---|-----|
| | 9.19 | Histopathology of Skin | 372 |
| | 9.20 | Stability study | 374 |
| | 9.21 | References | 379 |
| Chapter-10: In vivo Studies | | | |
| 10.0 | 10.1 | Introduction | 385 |
| | 10.2 | Materials and methods | 385 |
| | 10.2.1 | Materials | 385 |
| | 10.2.2 | Animal study protocol approval | 385 |
| | 10.2.3 | Animal Procurement | 385 |
| | 10.3 | In vivo pharmacokinetic studies | 386 |
| | 10.3.1 | Sample administered | 387 |
| | 10.3.2 | Blood sample collection | 387 |
| | 10.3.3 | Preparation of sample for analysis | 387 |
| | 10.3.4 | Analysis of pharmacokinetic parameters | 388 |
| | 10.4 | In vivo pharmacodynamic studies | 388 |
| | 10.4.1 | Induction of osteoporosis | 389 |
| | 10.5 | Antiosteoporotic treatment | 390 |
| | 10.6 | Evaluation of Antiosteoporotic activity | 391 |
| | 10.7 | Results and discussion | 394 |
| | 10.7.1 | In vivo pharmacokinetic study | 394 |
| | 10.7.2 | In vivo pharmacodynamic studies | 401 |
| | 10.7.2.1 | Radiological analysis | 401 |
| | 10.7.2.2 | Bone weight, bone volume and bone density | 405 |
| | 10.7.2.3 | Biochemical assay | 407 |
| | 10.7.2.4 | Histopathology of bones | 410 |
| | 10.9 | References | 416 |
| Chapter-11: Summary and conclusions | | | |
| 11.0 | 11.1 | Summary | 422 |
| | 11.1.1 | Introduction | 422 |
| | 11.1.2 | Analytical techniques | 424 |
| | 11.1.3 | Preformulation studies | 424 |
| | 11.1.4 | ATO loaded glycosomes | 425 |
| | 11.1.5 | RSNa loaded glycosomes | 426 |
| | 11.1.6 | ATO loaded PECN | 427 |
| | 11.1.7 | RSNa loaded PECN | 428 |
| | 11.1.8 | Nanocarriers incorporated transdermal patches | 429 |
| | 11.1.9 | In vivo pharmacokinetic and pharmacodynamic study | 432 |
| | 11.2 | Conclusions | 433 |

CONTENTS

| | | | |
|-----------------|-----------|-------------------------------|------------|
| Appendix | I | List of Publications | 435 |
| Appendix | II | Plagiarism Certificate | 437 |